tci Part B Insider - 2005 Issue 10

Tysabri Pulled From Market

Physicians have been optimistic about the possibilities of using Tysabri to treat multiple sclerosis (see PBI, Vol. 6, no. 6). But now Biogen Idec and Elan Pharmaceuticals, the makers of Tysabri, have temporarily pulled the drug from the market.In a Feb. 28 announcement, Biogen and Elan announced that they "are suspending supply of Tysabri from commercial distribution and physicians should suspend dosing of Tysabri until further notification." The suspension follows "recent reports of two serious adverse events that have occurred in patients treated with Tysabri in combination with Avonex (Interferon beta-1a) in clinical trials," including at...

To read the full article, sign in and subscribe to tci Part B Insider.


Keep pace with evolving Medicare regulations with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI’s Part B Insider will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, the fee schedule, OIG target areas, and more.

  • Current newsletters added each month
  • Fully searchable archives - over 4800 articles
  • ALL years/issues back to 2003 organized by year and issue
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles

This feature is currently unavailable for online purchase. For more information, please call 801-770-4203 or Contact Us.

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.